Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 447, 17 (3 May 2007) | doi:10.1038/447017a; Published online 2 May 2007
In brief
British drug firm AstraZeneca said it would pay a cool US$15.6 billion to acquire MedImmune, a biotechnology company based in Gaithersburg, Maryland, whose main product is a nasal-spray flu vaccine.
To read this story in full you will need to login or make a payment (see right).